EGFR and non-small cell lung carcinoma: Compared to the first-generation anticancer agents, Dacomitinib has prolonged progression-free survival and overcame the resistance from the EGFR-muted NSCLC (Gonzales et al., 2008; Lau et al., 2019) but at the expense of increased cytotoxicity (Zugazagoitia et al., 2017).